The Filing Desk

CAMP4 Therapeutics vs Marker Therapeutics

CAMP4 Therapeutics CAMP · Marker Therapeutics MRKR · Pharmaceuticals

CAMP4 Therapeutics reported revenue of $4 million in fiscal 2025, about the same as Marker Therapeutics' $4 million in fiscal 2025. CAMP4 Therapeutics' revenue grew 436.5% in its latest year, and Marker Therapeutics' fell 46.2%. CAMP4 Therapeutics had an operating margin of -1502.4%, against -363.4% at Marker Therapeutics.

Side by side

CAMP4 TherapeuticsMarker Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4M$4M
Revenue growth436.5%−46.2%
Revenue growth a year, last 5 years—47.6%
Gross margin——
Operating margin−1,502.4%−363.4%
Net margin−2,298.5%−343.0%
Free cash flow−$30M—
Free cash flow margin−852.8%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count547.8%70.5%
Last close$4.00$1.32
P/E at the last close——
Insider trades, last 12 monthsbought $77,433, sold $2.5 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CAMP4 TherapeuticsMarker Therapeutics
Operating margin
Percent of revenue
CAMP4 TherapeuticsMarker Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CAMP4 TherapeuticsMarker Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CAMP4 Therapeutics and Marker Therapeutics pages.